 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MNPR-101 Radiopharma Program to Enter First-in-Human Studies Potentially As Early As December of This Year Camsirubicin Phase 1b Trial Efficacy and Safety Data Highlighted at the 2023 CTOS Annual...

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...

Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR  Get Free Report) fell 1.4% during mid-day trading on Monday . The stock traded as low as $0.63 and last traded at $0.64. 12,200 shares traded...

Monopar Therapeutics (NASDAQ:MNPR)  Shares Down 1.4%

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR  Get Free Report) dropped 5.2% during trading on Friday . The company traded as low as $0.66 and last traded at $0.71. Approximately 36,785 shares were traded during trading, a decline of 84% from the average daily volume of 228,586 shares. The...

Monopar Therapeutics (NASDAQ:MNPR) Trading Down 5.2%

Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies WILMETTE, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-...

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

Monopar Therapeutics GAAP EPS of -$0.16 beats by $0.03

WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR),a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer,todayprovided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of ...

Monopar Provides Encouraging Camsirubicin Clinical Data Update

WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today announced a collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the ...

Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Watchers	1,736
52-Wk Low	$0.2739
52-Wk High	$3.82

Market Cap	$4.58M
Volume (M)	83,858.00
52-Wk High	$3.82
52-Wk Low	$0.2739

MNPR Monopar Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals

Sentiment

Message Volume

Community